Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
5005 Mcconnell Ave, Los Angeles, California
State of incorporation
Washington
Fiscal year end
December 31
Former names
AmpliPhi Biosciences Corp (to 5/8/2019), TARGETED GENETICS CORP /WA/ (to 2/11/2011)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 47.3 % -49.3%
Debt-to-equity -399 % -279%
Return On Equity 182 %
Return On Assets -61 % -64.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares +0.15%
Common Stock, Shares, Outstanding 36.2M shares +0.08%
Entity Public Float 12.5M USD -70.2%
Common Stock, Value, Issued 362K USD +0.28%
Weighted Average Number of Shares Outstanding, Basic 36.2M shares +0.24%
Weighted Average Number of Shares Outstanding, Diluted 58.2M shares +3.01%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13.4M USD +62%
Operating Income (Loss) -42.1M USD -5.34%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -67M USD -81.4%
Earnings Per Share, Basic -1.85 USD/shares -81.4%
Earnings Per Share, Diluted -2.28 USD/shares -109%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.4M USD +112%
Other Assets, Current 1.24M USD -85.6%
Assets, Current 30.9M USD +15.2%
Property, Plant and Equipment, Net 13.5M USD +53%
Operating Lease, Right-of-Use Asset 43.7M USD +0.04%
Intangible Assets, Net (Excluding Goodwill) 10.3M USD 0%
Goodwill 3.49M USD 0%
Other Assets, Noncurrent 1.04M USD -57.6%
Assets 108M USD +7.02%
Accounts Payable, Current 1.74M USD
Liabilities, Current 123M USD +139%
Deferred Income Tax Liabilities, Net 3.08M USD 0%
Operating Lease, Liability, Noncurrent 28.2M USD +2.65%
Liabilities 154M USD +88.2%
Retained Earnings (Accumulated Deficit) -325M USD -26%
Stockholders' Equity Attributable to Parent -46.1M USD -341%
Liabilities and Equity 108M USD +7.02%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +39.8%
Net Cash Provided by (Used in) Financing Activities 34.9M USD +18%
Net Cash Provided by (Used in) Investing Activities -250K USD +87.6%
Common Stock, Shares Authorized 217M shares 0%
Common Stock, Shares, Issued 36.2M shares +0.08%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 24.1M USD +141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.9M USD +75.4%
Operating Lease, Liability 34.8M USD
Depreciation 1.2M USD +37.3%
Payments to Acquire Property, Plant, and Equipment 250K USD -87.6%
Lessee, Operating Lease, Liability, to be Paid 69.6M USD
Property, Plant and Equipment, Gross 25.9M USD +27.3%
Operating Lease, Liability, Current 6.6M USD -54.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.47M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 5.31M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 34.9M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.45M USD
Deferred Tax Assets, Operating Loss Carryforwards 42.5M USD +16.8%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.62M USD
Operating Lease, Payments 3.36M USD -35.4%
Additional Paid in Capital 278M USD +0.65%
Depreciation, Depletion and Amortization 317K USD +37.8%
Share-based Payment Arrangement, Expense 1.69M USD -39.3%
Interest Expense 2.72M USD